The effect of infliximab dose escalation in inflammatory bowel disease patients with antibodies to infliximab

Conclusions A strategy of DE for selected patients receiving infliximab is associated with an increase in drug levels and reduced ATI positivity. This is associated with clinical remission in approximately 70% of patients at 6 months.
Source: European Journal of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Original articles: Gastroenterology Source Type: research